Clinical Trial Update: Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL [Phase 2]

View source ↗

Summary

A Phase 2 trial studying Copanlisib in combination with Ibrutinib or Acalabrutinib for relapsed/refractory Chronic Lymphocytic Leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Acalabrutinib (acalabrutinib)
• Copanlisib (copanlisib)
• Ibrutinib (ibrutinib)

Snippet

Sponsor: Inhye Ahn | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 2 | Status: WITHDRAWN